Cargando…

Risk of Trastuzumab-Related Cardiotoxicity in Early Breast Cancer Patients: A Prospective Observational Study

PURPOSE: In the present study, we investigated the incidence of cardiotoxicity within 5 years of trastuzumab treatment and evaluated potential risk factors in clinical practice. METHODS: The study cohort included 415 patients diagnosed with early breast cancer (EBC). Cardiotoxicity incidence was eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xue, Jian, Jiang, Zefei, Qi, Fan, Lv, Shuanghong, Zhang, Shaohua, Wang, Tao, Zhang, Xiaozhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278056/ https://www.ncbi.nlm.nih.gov/pubmed/25548585 http://dx.doi.org/10.4048/jbc.2014.17.4.363

Ejemplares similares

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
por: Marinko, Tanja, et al.
Publicado: (2014)

Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
por: Li, Feng, et al.
Publicado: (2021)

Trastuzumab Cardiotoxicity in Patients with Breast Cancer
por: Freitas, Aguinaldo Figueiredo, et al.
Publicado: (2014)

Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
por: Chang, Wei‐Ting, et al.
Publicado: (2021)

A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients
por: Matos, Erika, et al.
Publicado: (2016)

Early Cardiotoxicity after Adjuvant Concomitant Treatment with Radiotherapy and Trastuzumab in Patients with Breast Cancer
por: Marinko, Tanja, et al.
Publicado: (2018)

Detection of Subclinical Trastuzumab-Induced Cardiotoxicity in Patients with Breast Cancer
por: dos Santos, Marília Harumi Higuchi
Publicado: (2013)

Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
por: Méndez-Valdés, Gabriel, et al.
Publicado: (2023)

Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study
por: Zhao, Wei, et al.
Publicado: (2020)

Ginsenoside Rg2 Attenuated Trastuzumab-Induced Cardiotoxicity in Rats
por: Liu, Guang, et al.
Publicado: (2022)

Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay
por: Castillo, Cecilia, et al.
Publicado: (2022)

Coq10 for preventing cardiotoxicity in breast cancer patients treated with trastuzumab
por: Al-Hammadi, Nawal, et al.
Publicado: (2023)

Biomarker panel for early screening of trastuzumab -induced cardiotoxicity among breast cancer patients in west virginia
por: Pillai, Sneha S., et al.
Publicado: (2022)

Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study
por: Kaboré, Elisé G., et al.
Publicado: (2019)

Trastuzumab-related cardiotoxicity: what do we know in 2020?
por: Liu, Jia, et al.
Publicado: (2020)

Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis
por: Jawa, Zeeshan, et al.
Publicado: (2016)

Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients
por: Sayan, Mutlay, et al.
Publicado: (2019)

Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
por: Shrivastva, Sarita, et al.
Publicado: (2023)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
por: de la Brassinne Bonardeaux, Orianne, et al.
Publicado: (2023)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
por: Hidalgo, Sylvana, et al.
Publicado: (2013)

Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity
por: Jiang, Jiangsong, et al.
Publicado: (2017)

Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer
por: Vazdar, Ljubica, et al.
Publicado: (2021)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Doxorubicin‐induced and trastuzumab‐induced cardiotoxicity in mice is not prevented by metoprolol
por: Nicol, Martin, et al.
Publicado: (2021)

Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
por: Eaton, Holden, et al.
Publicado: (2023)

Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
por: Zhou, Shijie, et al.
Publicado: (2023)

Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer
por: Sato, Akihiko, et al.
Publicado: (2019)

Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
por: Fabiani, Iacopo, et al.
Publicado: (2020)

NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients
por: Blancas, Isabel, et al.
Publicado: (2020)

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
por: Yang, Fan, et al.
Publicado: (2020)

How can clinical research help our understanding of trastuzumab-related cardiotoxicity?
por: Lyons, Tomás G., et al.
Publicado: (2015)

Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer
por: Arciniegas Calle, Maria C., et al.
Publicado: (2018)

Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters
por: Díaz‐Antón, Belén, et al.
Publicado: (2022)

Whole exome sequencing to identify genetic markers for trastuzumab‐induced cardiotoxicity
por: Udagawa, Chihiro, et al.
Publicado: (2018)

Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy
por: Gabani, Mohanad, et al.
Publicado: (2021)

Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
por: Acibuca, Aynur, et al.
Publicado: (2021)

Echocardiographic strategy for early detection of cardiotoxicity of doxorubicin: a prospective observational study
por: Sampaio, Diogo Pereira Santos, et al.
Publicado: (2022)

Evaluation of the Preventive Effects of Carvedilol on Trastuzumab-Induced Cardiotoxicity in Early-Stage and Locally Advanced HER2-Positive Breast Cancer Patients
por: Esfandbod, Mohsen, et al.
Publicado: (2021)

High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy
por: Katsurada, Kenichi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_565s427f45mlit3icc8jifuvch